Humira is an anti-TNF monoclonal antibody that currently treats Crohn's disease, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis and uveitis.

Type of Molecule

Biologic

Target

TNF

Region

US, EU, Japan

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Hidradenitis Suppurativa (HS) (US, EU) New Indication Phase Approved Approved
Uveitis (US, EU, JAPAN) New Indication Phase Approved Approved